LAB:NASDAQ, Standard BioTools Inc.

Why LAB stock fell on November 16

Standard BioTools Inc. fell 12.2% on Monday, November 16, 2026, on 639,075 shares. No headline about LAB came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

LAB stock overview

Standard BioTools Inc. (LAB:NASDAQ) closed at $0.621 on November 16, 2026, down 12.21% on the day. The stock trades 63.9% below its 52-week high of $1.72 and 5.3% above its 52-week low of $0.590. Over the past year, it lost 49.9%. Standard BioTools Inc. is part of the Capital Goods sector.

Key figures

Price
$0.621
Day change
-12.21%
Volume
639,075
Average volume
1,182,882
Market cap
245M+
52-week range
$0.590 – $1.72
50-day average
$0.678
200-day average
$0.871

Price action over the past year

In 252 trading sessions since November 14, 2025, LAB closed higher on 98 days (39%). Its best day was January 8, 2026 (+20.31%) and its worst was June 8, 2026 (-30.43%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

LAB news

About Standard BioTools Inc.

Fluidigm Corp manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. It sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of Consumables. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of revenue is generated in the United States followed by EMEA and Asia-Pacific.

Similar stocks

Find more stocks like LAB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.